COVID-19UMODCOVID19NCT04316884
Mechanisms for Organ Dysfunction in Covid-19
An observational study of COVID-19 and Organ Dysfunction Syndrome Sepsis, run by Uppsala University at 1 site in Sweden.
Trial summary
The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19, Organ Dysfunction Syndrome Sepsis, Organ Dysfunction Syndrome, Multiple
- How many people
- 380 participants
- Where
- 1 siteSweden
- Study dates
- 12 Mar 2020to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients requiring intensive care with suspected or verified COVID19
Who may be able to join
- Admitted to intensive care
- suspected or verified COVID-19
Who cannot join
- Pregnancy or breastfeeding
- Under-age
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19
The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
Read the detailed description
Consenting patients with suspected or verified SARS-COV-2 infection, COVID-19, will undergo daily blood, urine and sputum sampling during their stay in intensive care. Data on organ dysfunction will be collected through the electronic patient journal and electronic patient data management system. The collected samples will be analysed for a panel of potential biomarkers that will be correlated to organ dysfunction and clinical outcome.
- Conditions
- COVID-19, Organ Dysfunction Syndrome Sepsis, Organ Dysfunction Syndrome, Multiple, Septic Shock, Acute Kidney Injury, Acute Respiratory Distress Syndrome
- Medical subject headings
- COVID-19, Toxemia, Multiple Organ Failure, Shock, Septic, Acute Kidney Injury, Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| COVID-19 | Patients with suspected or verified COVID-19 admitted to intensive care at Uppsala University Hospital |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acute Kidney Injury
KDIGO AKI score
Measured: During Intensive Care, an estimated average of 10 days.
Secondary outcomes (7)
ARDS
Acute Respiratory Distress Syndrome yes/no
Measured: During intensive care, an estimated average of 10 days.
30 day mortality
Death within 30 days of ICU admission
Measured: 30 days
1 year mortality
Death within 1 year of ICU admission
Measured: 1 year
Chronic Kidney Disease
Development of Chronic Kidney Disease
Measured: 60 days and 1 year after ICU admission
SOFA-score
Sequential Organ Failure Score as a continuous variable
Measured: During Intensive Care, an estimated average of 10 days.
Thromboembolic events
Occurence of thrombosis and/or embolous
Measured: During intensive care
ICUAW
Intensive care acquired weakness
Measured: During intensive care or after intensive care
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2020
- Study start12 Mar 2020
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (27)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 380 participants (actual)
Sponsor and investigators
- Lead sponsor
- Uppsala University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Robert Frithiof, Uppsala University
- Investigators
- Robert Frithiof, MD. PhD, Principal investigator, Uppsala University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04316884
- Sponsor's protocol ID
- EPN 2017/043 Covid19
- Acronym
- UMODCOVID19
- Status last verified
- Jan 2026
- First submitted
- 13 Mar 2020
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: IPD may be made available upon reasonable request.
Publications
Hultstrom M, von Seth M, Frithiof R. Hyperreninemia and low total body water may contribute to acute kidney injury in COVID-19 patients in intensive care. J Hypertens. 2020 Aug;38(8):1613-1614. doi: 10.1097/HJH.0000000000002531. No abstract available.
PubMed 32472780Hultstrom M, Persson B, Eriksson O, Lipcsey M, Frithiof R, Nilsson B. Blood type A associates with critical COVID-19 and death in a Swedish cohort. Crit Care. 2020 Aug 12;24(1):496. doi: 10.1186/s13054-020-03223-8. No abstract available.
PubMed 32787887Eriksson O, Hultstrom M, Persson B, Lipcsey M, Ekdahl KN, Nilsson B, Frithiof R. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb Haemost. 2020 Dec;120(12):1720-1724. doi: 10.1055/s-0040-1715835. Epub 2020 Sep 1.
PubMed 32871607Stattin K, Lipcsey M, Andersson H, Ponten E, Bulow Anderberg S, Gradin A, Larsson A, Lubenow N, von Seth M, Rubertsson S, Hultstrom M, Frithiof R. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients. J Crit Care. 2020 Dec;60:249-252. doi: 10.1016/j.jcrc.2020.08.026. Epub 2020 Sep 3.
PubMed 32920503Frithiof R, Bergqvist A, Jarhult JD, Lipcsey M, Hultstrom M. Presence of SARS-CoV-2 in urine is rare and not associated with acute kidney injury in critically ill COVID-19 patients. Crit Care. 2020 Sep 29;24(1):587. doi: 10.1186/s13054-020-03302-w. No abstract available.
PubMed 32993742Asif S, Frithiof R, Lipcsey M, Kristensen B, Alving K, Hultstrom M. Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care. Crit Care. 2020 Nov 6;24(1):639. doi: 10.1186/s13054-020-03362-y. No abstract available.
PubMed 33158455Luther T, Bulow-Anderberg S, Larsson A, Rubertsson S, Lipcsey M, Frithiof R, Hultstrom M. COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury. Acta Anaesthesiol Scand. 2021 Mar;65(3):364-372. doi: 10.1111/aas.13746. Epub 2020 Nov 28.
PubMed 33190222Bulow Anderberg S, Luther T, Berglund M, Larsson R, Rubertsson S, Lipcsey M, Larsson A, Frithiof R, Hultstrom M. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine. 2021 Feb;138:155389. doi: 10.1016/j.cyto.2020.155389. Epub 2020 Dec 14.
PubMed 33348065Zhou S, Butler-Laporte G, Nakanishi T, Morrison DR, Afilalo J, Afilalo M, Laurent L, Pietzner M, Kerrison N, Zhao K, Brunet-Ratnasingham E, Henry D, Kimchi N, Afrasiabi Z, Rezk N, Bouab M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, Abdullah T, Almamlouk N, Chen Y, Chasse M, Durand M, Paterson C, Normark J, Frithiof R, Lipcsey M, Hultstrom M, Greenwood CMT, Zeberg H, Langenberg C, Thysell E, Pollak M, Mooser V, Forgetta V, Kaufmann DE, Richards JB. A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. Nat Med. 2021 Apr;27(4):659-667. doi: 10.1038/s41591-021-01281-1. Epub 2021 Feb 25.
PubMed 33633408Lipcsey M, Persson B, Eriksson O, Blom AM, Fromell K, Hultstrom M, Huber-Lang M, Ekdahl KN, Frithiof R, Nilsson B. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. Front Immunol. 2021 Feb 22;12:627579. doi: 10.3389/fimmu.2021.627579. eCollection 2021.
PubMed 33692801Jarhult JD, Hultstrom M, Bergqvist A, Frithiof R, Lipcsey M. The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients. Sci Rep. 2021 Mar 30;11(1):7163. doi: 10.1038/s41598-021-86500-y.
PubMed 33785784Frithiof R, Rostami E, Kumlien E, Virhammar J, Fallmar D, Hultstrom M, Lipcsey M, Ashton N, Blennow K, Zetterberg H, Punga AR. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clin Neurophysiol. 2021 Jul;132(7):1733-1740. doi: 10.1016/j.clinph.2021.03.016. Epub 2021 Apr 1.
PubMed 33875374Galien S, Hultstrom M, Lipcsey M, Stattin K, Frithiof R, Rosen J; Uppsala Intensive Care COVID-19 Research Group. Point of care ultrasound screening for deep vein thrombosis in critically ill COVID-19 patients, an observational study. Thromb J. 2021 Jun 2;19(1):38. doi: 10.1186/s12959-021-00272-z.
PubMed 34078399Gradin A, Andersson H, Luther T, Anderberg SB, Rubertsson S, Lipcsey M, Aberg M, Larsson A, Frithiof R, Hultstrom M. Urinary cytokines correlate with acute kidney injury in critically ill COVID-19 patients. Cytokine. 2021 Oct;146:155589. doi: 10.1016/j.cyto.2021.155589. Epub 2021 May 24.
PubMed 34161857Huckriede J, Anderberg SB, Morales A, de Vries F, Hultstrom M, Bergqvist A, Ortiz-Perez JT, Sels JW, Wichapong K, Lipcsey M, van de Poll M, Larsson A, Luther T, Reutelingsperger C, de Frutos PG, Frithiof R, Nicolaes GAF. Evolution of NETosis markers and DAMPs have prognostic value in critically ill COVID-19 patients. Sci Rep. 2021 Aug 3;11(1):15701. doi: 10.1038/s41598-021-95209-x.
PubMed 34344929
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19
- ClinicalTrials.gov ID
- NCT04316884
- Acronym / sponsor ID
- UMODCOVID19 / EPN 2017/043 Covid19
- Conditions
- COVID-19, Organ Dysfunction Syndrome Sepsis, Organ Dysfunction Syndrome, Multiple, Septic Shock, Acute Kidney Injury, Acute Respiratory Distress Syndrome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 380 participants (actual)
- Lead sponsor
- Uppsala UniversityUniversity, hospital or other
- Study start
- 12 Mar 2020 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 20 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
Detailed description
Consenting patients with suspected or verified SARS-COV-2 infection, COVID-19, will undergo daily blood, urine and sputum sampling during their stay in intensive care. Data on organ dysfunction will be collected through the electronic patient journal and electronic patient data management system. The collected samples will be analysed for a panel of potential biomarkers that will be correlated to organ dysfunction and clinical outcome.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| COVID-19 | – | –Patients with suspected or verified COVID-19 admitted to intensive care at Uppsala University Hospital |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients requiring intensive care with suspected or verified COVID19
Key inclusion criteria (2 listed)
- Admitted to intensive care
- suspected or verified COVID-19
Key exclusion criteria (2 listed)
- Pregnancy or breastfeeding
- Under-age
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Acute Kidney Injury
Time frame: During Intensive Care, an estimated average of 10 days.
KDIGO AKI score
7 secondary outcomes
ARDS
Time frame: During intensive care, an estimated average of 10 days.
30 day mortality
Time frame: 30 days
1 year mortality
Time frame: 1 year
Chronic Kidney Disease
Time frame: 60 days and 1 year after ICU admission
SOFA-score
Time frame: During Intensive Care, an estimated average of 10 days.
Thromboembolic events
Time frame: During intensive care
ICUAW
Time frame: During intensive care or after intensive care
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
- Results publication: PubMed 32472780Hultstrom M, von Seth M, Frithiof R. Hyperreninemia and low total body water may contribute to acute kidney injury in COVID-19 patients in intensive care. J Hypertens. 2020 Aug;38(8):1613-1614. doi: 10.1097/HJH.0000000000002531. No abstract available.
- Results publication: PubMed 32787887Hultstrom M, Persson B, Eriksson O, Lipcsey M, Frithiof R, Nilsson B. Blood type A associates with critical COVID-19 and death in a Swedish cohort. Crit Care. 2020 Aug 12;24(1):496. doi: 10.1186/s13054-020-03223-8. No abstract available.
- Results publication: PubMed 32871607Eriksson O, Hultstrom M, Persson B, Lipcsey M, Ekdahl KN, Nilsson B, Frithiof R. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thromb Haemost. 2020 Dec;120(12):1720-1724. doi: 10.1055/s-0040-1715835. Epub 2020 Sep 1.
- Results publication: PubMed 32920503Stattin K, Lipcsey M, Andersson H, Ponten E, Bulow Anderberg S, Gradin A, Larsson A, Lubenow N, von Seth M, Rubertsson S, Hultstrom M, Frithiof R. Inadequate prophylactic effect of low-molecular weight heparin in critically ill COVID-19 patients. J Crit Care. 2020 Dec;60:249-252. doi: 10.1016/j.jcrc.2020.08.026. Epub 2020 Sep 3.
- Results publication: PubMed 32993742Frithiof R, Bergqvist A, Jarhult JD, Lipcsey M, Hultstrom M. Presence of SARS-CoV-2 in urine is rare and not associated with acute kidney injury in critically ill COVID-19 patients. Crit Care. 2020 Sep 29;24(1):587. doi: 10.1186/s13054-020-03302-w. No abstract available.
- Results publication: PubMed 33158455Asif S, Frithiof R, Lipcsey M, Kristensen B, Alving K, Hultstrom M. Weak anti-SARS-CoV-2 antibody response is associated with mortality in a Swedish cohort of COVID-19 patients in critical care. Crit Care. 2020 Nov 6;24(1):639. doi: 10.1186/s13054-020-03362-y. No abstract available.
- Results publication: PubMed 33190222Luther T, Bulow-Anderberg S, Larsson A, Rubertsson S, Lipcsey M, Frithiof R, Hultstrom M. COVID-19 patients in intensive care develop predominantly oliguric acute kidney injury. Acta Anaesthesiol Scand. 2021 Mar;65(3):364-372. doi: 10.1111/aas.13746. Epub 2020 Nov 28.
- Results publication: PubMed 33348065Bulow Anderberg S, Luther T, Berglund M, Larsson R, Rubertsson S, Lipcsey M, Larsson A, Frithiof R, Hultstrom M. Increased levels of plasma cytokines and correlations to organ failure and 30-day mortality in critically ill Covid-19 patients. Cytokine. 2021 Feb;138:155389. doi: 10.1016/j.cyto.2020.155389. Epub 2020 Dec 14.
- Results publication: PubMed 33633408Zhou S, Butler-Laporte G, Nakanishi T, Morrison DR, Afilalo J, Afilalo M, Laurent L, Pietzner M, Kerrison N, Zhao K, Brunet-Ratnasingham E, Henry D, Kimchi N, Afrasiabi Z, Rezk N, Bouab M, Petitjean L, Guzman C, Xue X, Tselios C, Vulesevic B, Adeleye O, Abdullah T, Almamlouk N, Chen Y, Chasse M, Durand M, Paterson C, Normark J, Frithiof R, Lipcsey M, Hultstrom M, Greenwood CMT, Zeberg H, Langenberg C, Thysell E, Pollak M, Mooser V, Forgetta V, Kaufmann DE, Richards JB. A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. Nat Med. 2021 Apr;27(4):659-667. doi: 10.1038/s41591-021-01281-1. Epub 2021 Feb 25.
- Results publication: PubMed 33692801Lipcsey M, Persson B, Eriksson O, Blom AM, Fromell K, Hultstrom M, Huber-Lang M, Ekdahl KN, Frithiof R, Nilsson B. The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. Front Immunol. 2021 Feb 22;12:627579. doi: 10.3389/fimmu.2021.627579. eCollection 2021.
- Results publication: PubMed 33785784Jarhult JD, Hultstrom M, Bergqvist A, Frithiof R, Lipcsey M. The impact of viremia on organ failure, biomarkers and mortality in a Swedish cohort of critically ill COVID-19 patients. Sci Rep. 2021 Mar 30;11(1):7163. doi: 10.1038/s41598-021-86500-y.
- Results publication: PubMed 33875374Frithiof R, Rostami E, Kumlien E, Virhammar J, Fallmar D, Hultstrom M, Lipcsey M, Ashton N, Blennow K, Zetterberg H, Punga AR. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clin Neurophysiol. 2021 Jul;132(7):1733-1740. doi: 10.1016/j.clinph.2021.03.016. Epub 2021 Apr 1.
- Individual participant dataSharing planned: Undecided. IPD may be made available upon reasonable request.
Related trials for COVID-19
RecruitingPhase 3
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
SARS-CoV-2
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Active, not recruiting
Motivational Interviewing Intervention for Families With Overweight and Obesity
Obesity & Overweight
Active, not recruiting
Lupus Education Alliance Program
Systemic Lupus Erythematosus, COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert Frithiof, MD. PhD principal investigator
Uppsala University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Organ Dysfunction Syndrome Sepsis, run by Uppsala University at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acute Kidney Injury (time frame: During Intensive Care, an estimated average of 10 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04316884, which also lists 27 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.